Strong Is the New Definition of Beautiful
Spread the loveStrong Is the New Definition of Beautiful Why women need strength training at every stage of life By Juthika Gupta | FITTR Coach Fitness is not simply about becoming smaller. It is about becoming stronger, more capable and more confident in the body you live in. There was a time when the dominant…
Eli Lilly’s $2.88 Billion Bet on Autoimmune Medicine
Spread the love Eli Lilly’s $2.88 Billion Bet on Autoimmune Medicine Inside the Merida Biosciences acquisition—and Lilly’s strategy to build its next growth engine beyond obesity By Jaano & Seekho Editorial Desk September 2026 A New Chapter Beyond Obesity For much of the pharmaceutical industry, few stories have been as transformative as Eli Lilly’s rise…
THE TRANSFORMATION ISSUE NAVLEEN KAUR GHAI
Spread the loveTHE TRANSFORMATION ISSUE NAVLEEN KAUR GHAI Beyond the Before-and-After How a 22-kg weight-loss journey became a story about health, resilience, strength—and finding a new purpose By Jaano & Seekho | Human Interest & Wellness Feature There is a temptation, whenever we see a transformation photograph, to look first at the body. We notice…
THE AI OPPORTUNITY BEYOND THE BILLION-DOLLAR BUDGET
Spread the loveTHE AI OPPORTUNITY BEYOND THE BILLION-DOLLAR BUDGET SmartSkale is betting that the next wave of AI adoption will not be defined by who spends the most—but by who makes AI genuinely useful. By SmartSkale | Business & Technology Feature Artificial intelligence has become one of the defining business technologies of the decade. Yet…
WHY LOOSE SKIN HAPPENS AFTER WEIGHT LOSS — AND HERE’S HOW TO MANAGE IT
Spread the loveWHY LOOSE SKIN HAPPENS AFTER WEIGHT LOSS — AND HERE’S HOW TO MANAGE IT Featuring Nupur Banerjee | Strength, Fitness & Embracing Your Transformation Weight loss is often celebrated as the final destination of a fitness journey. But for many people, the transformation doesn’t end when the number on the weighing scale comes…
NABARD-NaBFID MoU to Boost Rural Infrastructure Funding, Agri Value Chains
Spread the loveNABARD-NaBFID MoU: Rural Infrastructure Funding to Get a Major Boost Jannoandseekho.in | Agriculture Desk Published: August 28, 2026 NABARD and NaBFID Sign MoU to Strengthen Rural Infrastructure Financing The National Bank for Agriculture and Rural Development (NABARD) and the National Bank for Financing Infrastructure and Development (NaBFID) have signed a Memorandum of Understanding…
Advantech Puts Intel 18A Core Ultra Processors at the Center of Next-Generation Edge AI
Spread the loveAdvantech Puts Intel 18A Core Ultra Processors at the Center of Next-Generation Edge AI By JaanoAndSeekho.in Electronic News Desk International Technology News | August 28, 2026 Advantech expands its edge computing portfolio with Intel Core Ultra Series 3 processors, targeting real-time AI, machine vision and intelligent industrial automation. NEW DELHI/LONDON — Advantech is…
iPhone or Android? Your Smartphone Choice May Be More About Habit Than Brain Wiring
Spread the loveiPhone or Android? Your Smartphone Choice May Be More About Habit Than Brain Wiring By JaanoandSeekho Technology Desk For years, the debate between iPhone and Android users has sounded almost like a personality test. Some people say iPhone feels natural, while Android seems complicated. Others have the exact opposite reaction. It is tempting…
FDA Approves Priovant’s Lisraya for Rare Autoimmune Skin and Muscle Disease
Spread the loveFDA Approves Priovant’s Lisraya for Rare Autoimmune Skin and Muscle Disease Roivant-backed therapy becomes the first targeted treatment approved for adults with dermatomyositis By PharmaDesk International | JaanoAndSeekho.in August 28, 2026 The U.S. Food and Drug Administration (FDA) has approved brepocitinib, a dual TYK2/JAK1 inhibitor developed by Roivant-backed Priovant Therapeutics, for adults with…
FDA Greenlights Revolution Medicines’ Pancreatic Cancer Gamechanger
Spread the loveFDA Greenlights Revolution Medicines’ Pancreatic Cancer Gamechanger By PharmaDesk International | JaanoAndSeekho.in August 28, 2026 FDA approval marks a major milestone for targeted RAS therapy in metastatic pancreatic cancer The U.S. Food and Drug Administration (FDA) has approved Revolution Medicines’ RAS inhibitor daraxonrasib for the treatment of patients with metastatic pancreatic cancer, marking…
